

British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.

Over 30,000 patients registered in the study since 2001.

**NEW REGISTRATIONS AND FOLLOW-UP DATA IS SUBMITTED
ONLINE, DIRECTLY IN TO THE SECURE STUDY DATABASE.**

To sign up please visit <https://bsrbr.org/database/>

Eligibility for registration

	Diagnosis of Rheumatoid Arthritis		Aged 16 Years or over		Started eligible biologic treatment
--	--	---	------------------------------	--	--

ANTI-TNF COHORT	BIOSIMILARS	OTHER TARGETED THERAPIES
adalimumab originator* Humira	adalimumab biosimilars Amgevita Hulio Hyrimoz Idacio Imraldi Yuflyma	etanercept biosimilars Benepali Erelzi
etanercept originator* Enbrel	rituximab biosimilars Rixathon Ruxience Truxima	rituximab biosimilars Tyenne
infliximab originator* Remicade	infliximab biosimilars Flixabi Inflectra Remsima IV Remsima SC	tocilizumab biosimilars Benepali Erelzi
*patients must be biologic, biosimilar & targeted therapy naïve to be eligible		
rituximab originator MabThera		

Registration within
6 months of the
therapy start date*



*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Please contact the BSRBR-RA team with any questions

<https://bsrbr.org/> 0161 275 1652 biologics.register@manchester.ac.uk

https://twitter.com/BSRBR_RA